(SOBI) Swedish Orphan Biovitrum - Ratings and Ratios

Swedish Orphan Biovitrum AB (publ), a leader in the biotechnology sector, specializes in the research, development, manufacturing, and distribution of innovative therapies for rare and serious diseases. The company operates across three main therapeutic areas: haematology, immunology, and specialty care, with a strong presence in Europe, North America, the Middle East, Asia, and Australia. Its product portfolio includes treatments for haemophilia, paroxysmal nocturnal haemoglobinuria, thrombocytopenia, and myelofibrosis, among others. Key products such as Alprolix, Elocta, and Aspaveli®/Empaveli have established the company as a significant player in addressing unmet medical needs in these fields.

In addition to its commercialized therapies, Swedish Orphan Biovitrum AB (publ) is actively involved in collaborations with major pharmaceutical companies, including Sanofi, Apellis Pharmaceuticals, and ADC Therapeutics, to advance its pipeline. The company is also developing next-generation treatments, such as BIVV001 for haemophilia A and Nirsevimab for respiratory syncytial virus, further solidifying its position in the biotech industry. With a history dating back to 1939, the company remains headquartered in Solna, Sweden, and continues to expand its global footprint through strategic partnerships and innovative research.

From a technical perspective, SOBIs stock is currently trading at 263.00 SEK, below its SMA200 of 305.85, indicating potential bearish sentiment. The SMA20 and SMA50 are 274.28 and 293.77, respectively, suggesting a downward trend in the short to medium term. The average trading volume over the past 20 days is 294,918 shares, with an ATR of 8.90, indicating moderate volatility.

Fundamentally, the companys market cap stands at 89,917.04M SEK, with a P/E ratio of 23.27 and a forward P/E of 18.66, signaling expectations of earnings growth. The P/B ratio of 2.34 reflects a premium valuation relative to book value, while the P/S ratio of 3.45 indicates a reasonable revenue multiple. The return on equity (RoE) of 9.64% suggests stable profitability.